Patients with T2DM may secrete a small amount of insulin by themselves; therefore, hypoglycemic medicines are frequently used to induce insulin secretion from pancreatic β-cells and ameliorate the resistance of effector cells to insulin. This evidence concerns the gene INS and type 2 diabetes mellitus.